Rituximab Inferior to Ocrelizumab for MS Relapse : vimarsana

The relapse rate among patients with relapsing-remitting multiple sclerosis who were treated with rituximab was higher than among those treated with ocrelizumab, results of a noninferiority study suggest.

Related Keywords

Denmark , Danish , Sanofi Genzyme , National Health , Novartis , Research Council , Danish Multiple Sclerosis Registry , Medical Research Council , Multiple Sclerosis Ms , Multiple Sclerosis , Us , Monoclonal Antibody , Etuximab , Ituximab , Antineoplastic Drug , Nti Cancer Agents , Evacizumab , Rlotinib , Efitinib , Matinib , U11248 , Unitinib , Rastuzumab , Biologic Therapy , Multiple Sclerosis Relapse , S Relapse , Elapse Of Multiple Sclerosis , Elapse Of Ms , Relapsing Remitting Multiple Sclerosis , Arms , Ultiple Sclerosis Relapsing Rem ,